Columbus, OH

Endocrinology Research Associates

Gastroparesis

Lipodystrophy

Congenital Generalized Lipodystrophy

Cushing Syndrome

Diabetes Mellitus

Type 1 Diabetes Mellitus

Syndrome

Migraine Disorders

Headache

Relamorelin

Metreleptin

Osilodrostat

Allergan

Aegerion Pharmaceuticals

Avulux

Gan and Lee Pharmaceuticals

Recordati

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

MYALEPT™ (metreleptin) has been approved as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy (MYALEPT Prescribing Information). This study is a multicenter, open-label, Phase 4 trial to provide an assessment of the immunogenicity associated with metreleptin and of any major potential risks due to development of antibodies to metreleptin. The study is being conducted to comply with a postmarketing requirement.

Immunogenicity of Metreleptin in Patients With Generalized Lipodystrophy

Endocrinology Research Associates | Columbus, OH

Site insights

Work at this site?

Active trials

Immunogenicity of Metreleptin in Patients With Generalized Lipodystrophy

Trial sponsors